Literature DB >> 1416117

Greater neuromuscular blocking potency of atracurium during hypothermic than during normothermic cardiopulmonary bypass.

C Diefenbach1, M Abel, W Buzello.   

Abstract

Previous studies drew attention to the greater neuromuscular blocking potency of atracurium during, than before or after, hypothermic cardiopulmonary bypass (CPB) while disregarding the periods of normothermic perfusion. We recorded the evoked twitch tension in 15 patients during nitrous oxide/narcotic anesthesia who were undergoing open heart surgery. Atracurium was injected as an initial bolus dose of 460 micrograms/kg. Waning neuromuscular blockade was enhanced by repeat injections of 138 micrograms/kg whenever the twitch tension attained 25% of control. During hypothermic (< 32 degrees C) and normothermic (> 34 degrees C) CPB, the times of onset of the maintenance doses were 57% and 18% longer, respectively, than before CPB (P < 0.05). Maintenance doses of atracurium were required every 24 +/- 4 min (mean +/- SD) before CPB, every 45 +/- 8 min (P < 0.05) during hypothermia, every 22 +/- 3 min during normothermic perfusion, and every 23 +/- 3 min after CPB. In conclusion, the patients' changing demand of atracurium paralleled the changes of temperature rather than the institution and cessation of CPB.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416117     DOI: 10.1213/00000539-199211000-00004

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

Review 1.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

Review 2.  Selecting neuromuscular-blocking drugs for elderly patients.

Authors:  Tristan M Cope; Jennifer M Hunter
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

3.  Normothermic cardiopulmonary bypass increases heparin requirements necessary to maintain anticoagulation.

Authors:  M H Ereth; B R Fisher; D J Cook; G A Nuttall; T A Orszulak; W C Oliver
Journal:  J Clin Monit Comput       Date:  1998-07       Impact factor: 2.502

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.